Two randomized Phase 3 trials
The RECONNECT program included more than 1,200 participants in the efficacy analysis and reported improvements in desire and desire-related distress versus placebo.
P—15 • Clinically established profile
PT-141
An educational overview of a cyclic melanocortin-receptor agonist whose central-signaling research led to a narrowly defined FDA-approved indication.
Name
PT-141
Also known as bremelanotide; the FDA-approved product is Vyleesi
- Scientific classification
- Synthetic cyclic heptapeptide and melanocortin-receptor agonist derived from alpha-melanocyte-stimulating hormone research
- Library family
- Neuroactive
- Regulatory status
- FDA approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder; it is not indicated for men, postmenopausal women, or enhancement of sexual performance
Compound overview
A centrally acting peptide with a specific clinical role and a broader receptor-research story.
PT-141 is the research name commonly used for bremelanotide, a cyclic peptide that activates melanocortin receptors involved in central neural signaling. Its development helped demonstrate that sexual desire can be studied through brain-based receptor pathways rather than only through reproductive hormones or blood-vessel responses.
Two large Phase 3 trials in premenopausal women with acquired, generalized hypoactive sexual desire disorder reported statistically significant improvements in sexual-desire scores and reductions in distress related to low desire. These results supported FDA approval of the Vyleesi product in 2019 for that specific population and condition.
Subsequent analyses have explored how results vary across participant groups and how clinical outcomes should be measured. A 2023 independent reanalysis described the average benefits as modest and questioned aspects of the outcome measures, reinforcing the importance of discussing both statistical results and their practical meaning.
Approval has clear boundaries
The FDA indication applies only to a specific group of premenopausal women with acquired, generalized HSDD—not to general performance enhancement or other populations.
Measuring meaningful change
Later analyses continue to examine the size, interpretation, and measurement of patient-reported benefits, helping refine future sexual-health research.
Mechanism under study
Central melanocortin-receptor signaling
Bremelanotide activates several melanocortin-receptor subtypes. MC4R is considered especially relevant at therapeutic exposure, although the exact pathway connecting receptor activation to improvement in HSDD symptoms remains incompletely defined.
Central receptor activation
MC4R is expressed in brain networks involved in motivation, appetite, autonomic regulation, and sexual response.
Desire and response pathways
Preclinical research suggests melanocortin signaling can influence hypothalamic and dopamine-related circuits associated with sexual motivation.
Wider receptor activity
Activity at additional melanocortin receptors helps explain why the compound has physiological effects beyond the intended central response.
Its approved clinical effect is considered centrally mediated. This does not mean every PT-141 product is equivalent to Vyleesi or that results extend beyond the labeled population.
Current research areas
Questions under investigation
- How the brain regulates sexual desire
- How MC4R signaling changes motivation and response
- Which patient-reported changes are most meaningful
- Why benefits and side effects vary among individuals
- Whether more selective receptor designs can improve future therapies
Evidence summary
A validated central-signaling concept with carefully defined limits
- Established clinical signal: Two randomized Phase 3 trials reported statistically significant improvements in sexual desire and reduced distress related to low desire.
- Defined nonhormonal pathway: Bremelanotide demonstrates a central melanocortin approach that does not depend on hormone replacement.
- Subgroup research: Follow-up analyses examined results across age, body weight, BMI, testosterone levels, and hormonal-contraceptive use within the studied population.
- Patient-centered measurement: The development program expanded research into how desire, distress, arousal, and the quality of sexual experiences should be measured.
- Broader receptor science: MC4R's roles in appetite, motivation, and autonomic signaling make bremelanotide useful for studying how one receptor network influences several biological systems.
- Next-generation design: Continued work on receptor selectivity may help researchers preserve desired central effects while reducing unwanted physiological responses.
Bremelanotide has stronger human evidence than most compounds in this library because an FDA-approved product exists. The benefit is indication-specific, average effects were modest, and treatment decisions require individualized clinical evaluation.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, prescribing guidance, dosing information, or instructions for PT-141 or bremelanotide use. FDA labeling identifies temporary blood-pressure increases, heart-rate reductions, nausea, flushing, headache, injection-site reactions, and possible focal hyperpigmentation. Vyleesi is contraindicated in people with uncontrolled hypertension or known cardiovascular disease and may slow absorption of certain oral medications. Products marketed as PT-141 should not be assumed to match the identity, quality, or evidence of the FDA-approved product.
Key scientific referencesComing soon
A curated primary-source reference list will be added during the next educational expansion.